Pharma

Your Article Summary

See Latest Articles

Corcept Therapeutics Announces Negative Results From the Second of Three Phase 3 Studies Evaluating CORLUX(R) for Treating the Psychotic Features of Psychotic Major Depression
Corporate News Releases - The Healthcare Sales & Marketing Network, 10/02/06

Corcept Therapeutics Incorporated announced that the second of its three Phase 3 trials evaluating CORLUX for treating the psychotic features of Psychotic Major Depression (PMD) was negative. Study 09 was a randomized, double-blind, placebo-controlled study

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial
European Heart Journal, 06/09/09

Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841
Journal of Clinical Oncology, 06/15/09

Rationale, design, and baseline characteristics of the Acetylcystein for Contrast-Induced nephropaThy (ACT) Trial: a pragmatic randomized controlled trial to evaluate the efficacy of acetylcysteine for the prevention of contrast-induced nephropathy
Trials, 06/05/09

See All of Drug Trials